Bjenning C A, Rimvall K
Health Care Discovery and Preclinical Development, Novo Nordisk, Måløv, Denmark.
Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S140-1. doi: 10.1038/sj.ijo.0801304.
It has previously been demonstrated that oCRF and the CRF binding protein inhibitor CRF (6-33) reduce body-weight gain in obese Zucker rats. We investigated whether the reduction in body-weight is attributable to altered feeding and drinking behaviour. Obese Zucker rats were fitted with osmotic mini-pumps connected to i.c.v. cannulas. Vehicle, oCRF (5 microg/day) or CRF (6-33) (25 microg/day) were infused for 7 days and the animals observed for an additional 7 days. Body-weight and food and water-intake were recorded daily at 14.00 h. In agreement with published results, oCRF and CRF (6-33) significantly reduced body-weight gain in the obese Zucker rat. In addition, food intake was reduced, whereas water consumption was unaffected.
先前已经证明，大鼠促肾上腺皮质激素释放因子（oCRF）和促肾上腺皮质激素释放因子结合蛋白抑制剂CRF（6-33）可减少肥胖Zucker大鼠的体重增加。我们研究了体重减轻是否归因于摄食和饮水行为的改变。给肥胖Zucker大鼠安装与脑室内插管相连的渗透微型泵。注入溶媒、oCRF（5微克/天）或CRF（6-33）（25微克/天），持续7天，并对动物再观察7天。每天14:00记录体重、食物和水的摄入量。与已发表的结果一致，oCRF和CRF（6-33）显著降低了肥胖Zucker大鼠的体重增加。此外，食物摄入量减少，而水的消耗量未受影响。
